60 likes | 70 Views
This project aims to develop an economically efficient cyclotron-based technology for the production of 44Sc radionuclide for medical diagnostics. The focus is on providing a clinical study platform for 44Sc-based imaging in neuroendocrine tumors and exploring theranostic pairing with 47Sc. The project involves technology development, production optimization, radiolabeling methods, quality control, and clinical validation in tumor patients.
E N D
44Sc production with 18 MeV cyclotron and jointstudy of scandium-labeled peptide based ligands for clinical use Assoc.prof. Maija Radzina, RīgaStradiņšUniversity,Radiology Research laboratory Mg.chem. Edgars Mamis, RīgaStradiņšUniversity,Nuclear MedicineClinic
Aimoftheproject – jointreserachactivity • The goalsof this project are: • To develop economically efficient middle energy (18 MeV) cyclotronbasedtechnology for production and purification of 44Sc radionuclide as a medical diagnostic isotope in comparison with generator based technology • To provide clinical study platform for 44Sc radionuclide based imaging in neuroendocrine tumors • Theranostic pairing – 44Sc + 47Sc and their validation in middle energy cyclotron based technology
DevelopmentoftechnologyDevelopeconomicaly efficient cyclotron manufactured 44Sc as a diagnostic radionuclide and labeling technique • 44Sc liquid andsolid target design and adjustment for 44Sc production with 18 MeV cyclotron; • Production and optimization of 44Sc production using solid target versus using liquid target; • Transfer of crude 44Sc from cyclotron to “hot lab” from solid target versus from liquid target;
Obtain pure, non-carrier added 44Sc by chemical purification versusmass separation with the help of MEDICIS; • Quality check of cyclotron-produced and purified 44Sc against reference sample of 44Sc from MEDICIS; • Developtechnologyandmethod for radiolabeling ofDOTA conjugated peptide (TOC & TATE)with44Sc.Productpurification and formulation; • Quality control – physical and chemical analysis of 44Sc-DOTA conjugated peptide-based ligand for cancer diagnostics; Phase I activities maybe initiated by thebeginning of 2019
JointClinicalresearchplatformVerification of use in clinicalmedicine – 2020/2021 • neuroendocrinetumourpatients for clinical validation of 44Sc-DOTATOC • Unknownprimary NEN • Stage 3 and 4 NEN • licencedmedical PET/CT facility of RSU Nuclear medicine clinic is able to perform in-human imaging studies and host the clinical study with 44Sc- DOTA peptides and cancer binding active substances on a neuroendocrine malignancy patient cohort for the proof of concept • InterestforTheranosticpairing – 44Sc + 47Sc and their validation in neuroendocrine tumors and possibly other malignancy groups